Cargando…
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Despite the great impact on long-term survival of some cancer patients, the immune checkpoint blockade (ICB) therapy is limited by its low response rates for most cancers. There is a pressing need for novel combination immunotherapies that overcome the resistance to current ICB therapies. Cytokines...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174717/ https://www.ncbi.nlm.nih.gov/pubmed/32351508 http://dx.doi.org/10.3389/fimmu.2020.00634 |